The US FDA is encouraging the use of adaptive clinical trial designs for regenerative medicine therapies, such as having sponsors study several investigational agents together for treatment of rare diseases.
The Center for Biologics Evaluation and Research describes its views on clinical trial designs in a draft guidance, Expedited Programs for Regenerative Medicine Therapies for Serious Conditions, released Nov....